SBIR/STTR Research Award
Improved methodologies to measure novel alcohol biomarkers in whole blood
Award amount
$210,484Program and phase
SBIR · Phase IAward year
2012Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHOENIX BIOSYSTEM, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NXDUD4NDDQ93
- Solicitation number
- AA11-004
- Topic code
- NIAAA
Research abstract
DESCRIPTION (provided by applicant): Phosphatidylethanol (PEth) is a phospholipid formed only in the presence of ethanol via the action of phospholipase D. It has been measured in whole blood and proposed as a marker of ethanol abuse due to its high specificity and low degradation rate. The mean half-life of PEth in blood from alcoholics was found to be 4 days, and PEth was still measurable after 2 weeks of sobriety. Our overall goal is to expand on our successful preliminary work and develop a sensitive, high throughput ELISA biomarker assay for PEth analysis in whole blood. Current methods of analysis of PEth are based on the high performance liquid chromatography-mass spectrometric methods. Unavailability of rapid assays for the detection and the lack ofstandardization of the tests have hampered the clinical use of these biomarkers. The final PEth ELISA product that would result from this application could have a significant impact in the study and management of alcohol use disorders. PUBLIC HEALTHRELEVANCE: Our overall goal is to expand on our successful preliminary work and develop a sensitive, high throughput ELISA biomarker assay for PEth analysis in whole blood.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- HPV POINT OF CARE MOLECULAR DIAGNOSTICS FOR LMICS
- RAPID POINT OF CARE MOLECULAR DIAGNOSTICS FOR HCV
- Low cost, automated smartphone based assay for semen analysis
- Rapid Nucleic Acid Test for Chlamydia in Resource Limited Settings
- POINT OF CARE HIV COMBO ASSAY
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
- DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)
- SBIR PHASE I - WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME
- THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
- Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
Research funding history
27 SBIR/STTR records share this UEI (2002–2022). Reported award amounts total $7,473,973. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Energy